The Sulfadiazine market in the second half of 2024 showed distinct regional patterns across global markets. In Q3’24, North American Sulfadiazine prices remained stable amid moderate pharmaceutical demand. This stability was attributed to well-managed supply chains and consistent production capabilities despite some economic challenges. In contrast, the APAC region, with China leading the way, experienced gradual price increases throughout the quarter. This upward movement resulted from heightened buying interest, improved trading activities, and sustained demand from the pharmaceutical sector. European markets moved in the opposite direction, with prices easing slightly due to decreased feedstock costs, which created favorable production economics.
The fourth quarter showed a strengthening trend across all regions. North American Sulfadiazine prices firmed up, supported by robust production capacities, effective inventory management, and steady demand from biopharmaceutical activities. The APAC region, particularly South Korea, saw the most notable price strengthening, initially triggered by logistical disruptions and production delays before stabilizing later in the quarter. European markets experienced significant growth driven by expanding pharmaceutical applications, including active pharmaceutical ingredients and drug formulations.